L-Sulforaphene是一种天然的异硫氰酸酯，具有抗炎、抗癌和抗氧化作用。
Cas No.:592-95-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
L-Sulforaphene is a natural isothiocyanate with anti-inflammatory, anticancer, and antioxidant effects. L-Sulforaphene regulates multiple signaling pathways such as Nrf2 and NF-κB. L-Sulforaphene can be used in research related to various cancers including liver cancer, breast cancer, lung cancer, esophageal cancer, and gastric cancer, as well as cardiovascular diseases[1-4].
In vitro, L-Sulforaphene (5-10μM) was used to treat 3T3-L1 preadipocytes for 2 days during the early stage of adipogenesis. L-Sulforaphene significantly inhibited lipid accumulation and adipocyte differentiation, and reduced the protein and mRNA expression of PPARγ and C/EBPα, while decreasing C/EBPβ protein levels through post-translational degradation[5]. L-Sulforaphene (20–60μM) was used to treat COV362 cells for 24–48 hours. L-Sulforaphene significantly inhibited cell viability and promoted apoptosis, while upregulating the expression of IGF2BP2 and FAS and downregulating the expression of KRT8 and METTL3[6].
In vivo, L-Sulforaphene (10mg/kg; once daily) was subcutaneously injected into PDX SCID mice implanted with esophageal cancer patient tumors for 6 weeks. L-Sulforaphene significantly reduced tumor size[7]. L-Sulforaphene (10mg/kg or 50mg/kg; every other day) was subcutaneously injected into PDX SCID mice for six weeks. L-Sulforaphene significantly reduced tumor volume[8].
References:
[1] Ye Q, Yan T, Shen J, et al. Sulforaphene targets NLRP3 inflammasome to suppress M1 polarization of macrophages and inflammatory response in rheumatoid arthritis. J Biochem Mol Toxicol. 2023 Jul;37(7):e23362.
[2] Zhang G, Jin C, Zhu Y, et al. Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway. Life Sci. 2020 Dec 15;263:118485.
[3] Liao Y, Yan Q, Cheng T, et al. Sulforaphene Inhibits Periodontitis through Regulating Macrophage Polarization via Upregulating Dendritic Cell Immunoreceptor. J Agric Food Chem. 2023 Oct 25;71(42):15538-15552.
[4] Yao H, Du Y, Jiang B, et al. Sulforaphene suppresses RANKL-induced osteoclastogenesis and LPS-induced bone erosion by activating Nrf2 signaling pathway. Free Radic Biol Med. 2023 Oct;207:48-62.
[5] Yang H, Kang MJ, Hur G, et al. Sulforaphene Suppresses Adipocyte Differentiation via Induction of Post-Translational Degradation of CCAAT/Enhancer Binding Protein Beta (C/EBPβ). Nutrients. 2020 Mar 13;12(3):758.
[6] Yu HY, Yang L, Liu YC, et al. Sulforaphene suppressed cell proliferation and promoted apoptosis of COV362 cells in endometrioid ovarian cancer. PeerJ. 2023 Nov 21;11:e16308.
[7] Zhang C, Wu Q, Yao K, et al. Sulforaphene suppresses oesophageal cancer growth through mitogen- and stress-activated kinase 2 in a PDX mouse model. Am J Cancer Res. 2023 Oct 15;13(10):4708-4720.
[8] Zhang C, Zhang J, Wu Q, et al. Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro. Cancer Cell Int. 2019 Dec 19;19:342.
L-Sulforaphene是一种天然的异硫氰酸酯，具有抗炎、抗癌和抗氧化作用。L-Sulforaphene调控Nrf2、NF-κB等多种信号通路。L-Sulforaphene可用于肝癌、乳腺癌、肺癌、食道癌和前胃癌等多种癌症以及心血管疾病的相关研究[1-4]。
在体外，L-Sulforaphene（5-10μM）在脂肪形成早期阶段处理3T3-L1前脂肪细胞2天。L-Sulforaphene显著抑制脂质积累和脂肪细胞分化，并降低PPARγ和C/EBPα的蛋白和mRNA表达，同时通过翻译后降解降低C/EBPβ蛋白水平[5]。L-Sulforaphene（20–60μM）处理COV362细胞24–48小时。L-Sulforaphene显著抑制细胞活力并促进细胞凋亡，同时上调IGF2BP2和FAS的表达，下调KRT8和METTL3的表达[6]。
在体内，L-Sulforaphene（10mg/kg；每天一次）皮下注射于植入食管癌患者肿瘤的PDX SCID小鼠，持续六周。L-Sulforaphene显著减少了肿瘤大小[7]。L-Sulforaphene（10mg/kg或50mg/kg；每两天一次）皮下注射于PDX SCID小鼠，持续六周。L-Sulforaphene显著减少了肿瘤体积[8]。
| Cell experiment [1]: | |
Cell lines | COV362 cells (human endometrioid ovarian cancer cell line) |
Preparation Method | COV362 cells were cultured in DMEM complete medium at 37°C with 5% CO₂. Cells were treated with L-Sulforaphene (20–60μM). |
Reaction Conditions | 20–60μM; 24-48h |
Applications | L-Sulforaphene dose-dependently reduced the viability of COV362 cells and promoted their apoptosis. L-Sulforaphene increased the mRNA levels of IGF2BP2 and FAS, while decreasing the mRNA levels of KRT8 and METTL3. L-Sulforaphene reversed the increases in cell viability and clonal expansion capacity as well as the decrease in apoptosis induced by METTL3 overexpression in COV362 cells. |
| Animal experiment [2]: | |
Animal models | C.B-17 severe combined immunodeficient (SCID) mice |
Preparation Method | PDX models were initiated by subcutaneous implantation of esophageal cancer fragments from a patient. When tumor volume reached approximately 150mm³, mice were randomly assigned to groups treated with vehicle or L-Sulforaphene injections. L-Sulforaphene (10mg/kg or 50mg/kg) was administered every other day for 6 weeks. |
Dosage form | 10mg/kg or 50mg/kg; subcutaneous; every other day for 6 weeks |
Applications | L-Sulforaphene treatment reduced the mean tumor volume and inhibited tumor growth in mice. Immunohistochemical assays showed lower phosphorylated cadherin expression in tumor tissues from the L-Sulforaphene groups compared to the control group. |
References: | |
| Cas No. | 592-95-0 | SDF | |
| 别名 | 莱菔素 | ||
| Canonical SMILES | CS(/C=C/CCN=C=S)=O | ||
| 分子式 | C6H9NOS2 | 分子量 | 175.3 |
| 溶解度 | DMF: 1 mg/ml,DMSO: 15 mg/ml,Ethanol: 20 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7045 mL | 28.5225 mL | 57.0451 mL |
| 5 mM | 1.1409 mL | 5.7045 mL | 11.409 mL |
| 10 mM | 570.5 μL | 2.8523 mL | 5.7045 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet